167 results about "Adenosine Phosphates" patented technology

The invention is directed to compositions and methods which permit the oral use of adenosine and adenosine phosphates for cardiovascular applications such as pulmonary artery hypertension, cardiac failure and other diseases. Certain compositions in accordance with the invention have enhanced AMP gastrointestinal bioavailability and thus efficacy. The invention prolongs the activity of adenosine and adenosine phosphates when administered intravenously. In particular, the invention contemplates methods of treating several human (as well as animal) cardiovascular and neurological medical conditions that could be improved by an effective amount of adenosine, ATP or AMP combined with dialkylaminoalcohols and their salts.

The invention discloses a manufacturing method of tribiofosfor, which comprises the following steps: reacting; inactivating; separating through resin; decoloring; hyperfiltering; crystallizing.

The invention belongs to the field of insecticides, and relates to an insecticidal and acaricidal composition containing an ATP synthetase inhibitor acaricide. The composition contains an active component A and an active component B, a weight part ratio of the component A to the component B is 1:99-99:1, the active component A is a compound I represented by a structural formula shown in the invention, and the active component B is selected from a mitochondrial adenosine triphosphate (ATP) synthetase inhibitor acaricide. The composition has the advantages of obvious synergy and resistance delaying, and can be used for controlling various insects.

The invention relates to control of biofilm development. Specifically, some embodiments of the present invention relate to control of bacterial biofilm formation through addition or breakdown of signal(s) that induce biofilm formation. More specifically, some embodiments of the present invention relate to control (e.g., promotion, prevention) of biofilm development by application or hydrolysis of adenosine triphospate (ATP), deoxyadenosine triphosphate (dATP), or derivatives or analogs thereof (e.g., through application or administration of an agent that hydrolyzes ATP, dATP, or derivatives or analogs thereof (e.g., apyrase)).

The invention provides a stable compound coenzyme preparation and a preparation method thereof. The main compositions and proportions of the stable compound coenzyme preparation are as follows: 90-120 U of coenzyme A (CoA), 0.1-0.3 mg / ml coenzyme I (NAD), 1-5 mg / ml glutathione (GSH), 1-2.5 mg / ml adenosine triphosphate (ATP), 1.8-12 mu g / ml flavin mononucleotide (FMN), 3-13 mu g / ml flavin adenine dinucleotide (FAD), 0.1-0.4 mg / ml adenosine diphosphate (ADP), 0.2-0.4 mg / ml adenosine monophosphate (AMP), 1.2-15 mu g / ml of adenosine methionine (SAM), 1-5 mg / ml calcium gluconate, 0.5-1.5 mg / ml cysteine hydrochloride, and 0.6-5 mg / ml mannitol. The preparation method overcomes the defects that high-speed centrifugalization is adopted, freeze-drying conditions are not clear and the product stability is poor in the existing method, and the stable compound coenzyme preparation is widely applied to the practices of preparing drugs for treating cardia-cerebrovascular diseases and digestive system diseases.

The invention encompasses compositions and methods for effectively treating and / or preventing diabetes and / or obesity. This is accomplished by totally addressing the multiple mechanisms that lead to such conditions. The invention includes compositions comprising a combination of agents that effectively suppress, regulate or interfere with the various biochemical processes and mechanisms that lead to diabetes and obesity. The inventive compositions used for administration to human and other mammalian subjects comprise (1) at least one agent capable of modulating expression and / or activity of one or more of peroxisome activated protein receptor gamma (PPAR-γ), CAAT / enhancer binding protein-α (C / EBPα) and Sterol Regulatory Element-Binding Protein (SREBP-1); (2) at least one agent capable of activating Wnt / β-catenin pathway; (3) at least one agent capable of activating the adenosine monophosphate-activated protein kinase (AMPK) signaling pathway; (4) at least one agent that inhibits the activity of pro-oxidants including reactive nitrogen species and reactive oxygen species (ROS); (5) at least one agent that suppresses one or more of inflammatory mediators including interleukins IL-1α, IL-1β, IL-6, NF-κB, TNF-α, matrix metalloproteinases (MMPs) and prostaglandin E2 (PGE2); (6) at least one agent capable of enhancing glucose transporter (GLUT4) and / or inhibiting glucose transporter GLUT2; (7) at least one agent that induces the expression of and / or activates adiponectin and (8) at least one agent that induces the expression of and / or activates sirtuin (SIRT1). The active agents for use herein are natural materials such as phytonutrients, vitamins and minerals. Compositions with combinations of such natural agents have the ability to prevent, reduce or treat diabetes and obesity by (a) clearing glucose and fatty acids from blood, (b) reducing the number of adipose cells and fat storage, (c) interfering with fat, glucose, and cholesterol biosynthesis, and (d) promoting fat and glucose oxidation.Since the present compositions are aimed toward normalizing metabolism and energy expenditure and managing oxidative stress and inflammation, they are also beneficial in relation to physical activity, in particular performance, endurance, fatigue and recovery during intensive and continuous exercise / exertion.

The invention provides an enzymatic reaction composition, a method of increasing the amount of adenosine triphosphate (ATP) in an enzymatic reaction and a method for synthesizing an amino acid or a derivative, polypeptide, enzyme or protein thereof by utilizing the adenosine triphosphate (ATP). According to the method, a first enzyme or an enzyme group and adenosine for producing adenosine monophosphate (AMP) are added during the enzymatic reaction so as to increase the amount of the adenosine triphosphate (ATP). The method and composition provided by the invention can increase the amount of the adenosine triphosphate (ATP), thereby improving the enzymatic reaction efficiency and reducing the cost.